Fig. 2
Cisplatin treatment reduced GC cell viability and induced adaptive ER stress in GCs and ovaries. A The viability of GCs treated with different concentrations of cisplatin. B CCK-8 analysis detected the viability of GCs treated with 20 μM cisplatin for different durations. C-D The protein levels of GRP78, XBP1s and CHOP in GCs treated with different concentrations of cisplatin. E–F The protein levels of GRP78, XBP1s and CHOP in POF ovaries. G-H The protein levels of GRP78, XBP1s and CHOP in GCs at different time points under 20 μM cisplatin treatment. I The mRNA levels of GRP78, ATF4 and CHOP in GCs at different time points under 20 μM cisplatin treatment. J IF to detect the expression of GRP78 in GCs in the control group, cisplatin treatment group, and 4-PBA cotreatment group. Bar, 50 μm. K ELISA to detect the E2 levels in GCs in the control group, cisplatin treatment group, and 4-PBA cotreatment group. n ≥ 3 for each group. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with the control group. # p < 0.05 compared with the cisplatin treatment group